Please login to read the full article.
Scrip Regulatory Affairs
EMA reflection paper on generic nanoparticle iron products: a case of bias by omission?
21 July 2011
David Snodin
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- EMA responds to criticism of reflection paper on non-clinical studies for generic nano-particle iron medicinal product applications
- EU scientific panel to undertake risk assessment of medical devices containing nanomaterials
- New Swiss requirements on submissions for generics and products with known APIs get industry thumbs up
- IOM report suggests how to fix weaknesses in US paediatrics laws
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
EDITORIALS
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Other Informa Comments
